Elekta（EJXB）株式概要エレクタAB（publish）は医療技術企業で、がんや脳障害の治療のための臨床ソリューションの提供を世界中で行っている。 詳細EJXB ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長4/6過去の実績0/6財務の健全性2/6配当金3/6報酬当社が推定した公正価値より47.6%で取引されている 収益は年間42.17%増加すると予測されています リスク分析利払いは収益で十分にカバーされない 4.64%の配当は利益で十分にカバーされていない すべてのリスクチェックを見るEJXB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW491,718 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG491,718 investors already sharing narrativesYour Fair Value€Current Price€4.4661.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-519m21b2016201920222025202620282031Revenue SEK 20.5bEarnings SEK 2.7bAdvancedSet Fair ValueView all narrativesElekta AB (publ) 競合他社Drägerwerk KGaASymbol: XTRA:DRW3Market cap: €1.5bCarl Zeiss MeditecSymbol: XTRA:AFXMarket cap: €2.4bOttobock SE KGaASymbol: XTRA:OBCKMarket cap: €3.4bEckert & ZieglerSymbol: XTRA:EUZMarket cap: €994.3m価格と性能株価の高値、安値、推移の概要Elekta過去の株価現在の株価SEK 4.4652週高値SEK 5.8152週安値SEK 3.73ベータ0.951ヶ月の変化-8.38%3ヶ月変化-9.39%1年変化4.16%3年間の変化-33.14%5年間の変化-64.41%IPOからの変化107.27%最新ニュースRecent Insider Transactions • Jul 01Chief Product & Technology Officer recently bought €98k worth of stockOn the 26th of June, Christopher Busch bought around 23k shares on-market at roughly €4.27 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €373k more in shares than they have sold in the last 12 months.Declared Dividend • May 31Final dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 4th September 2026 Payment date: 10th September 2026 Dividend yield will be 27%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (66% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time.Reported Earnings • May 28Full year 2026 earnings released: kr1.36 loss per share (vs kr0.62 profit in FY 2025)Full year 2026 results: kr1.36 loss per share (down from kr0.62 profit in FY 2025). Revenue: kr16.7b (down 7.2% from FY 2025). Net loss: kr519.0m (down 319% from profit in FY 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.お知らせ • May 28+ 2 more updatesElekta AB (publ) Provides Earnings Guidance for the Fiscal Year 2026/2027Elekta AB (publ) provided earnings guidance for the fiscal year 2026/2027. For the year, The company expects net sales in constant currency to increase year over year, with an improvement in the EBIT margin.Board Change • May 21High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jan De Witte was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026最新情報をもっと見るRecent updatesRecent Insider Transactions • Jul 01Chief Product & Technology Officer recently bought €98k worth of stockOn the 26th of June, Christopher Busch bought around 23k shares on-market at roughly €4.27 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €373k more in shares than they have sold in the last 12 months.Declared Dividend • May 31Final dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 4th September 2026 Payment date: 10th September 2026 Dividend yield will be 27%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (66% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time.Reported Earnings • May 28Full year 2026 earnings released: kr1.36 loss per share (vs kr0.62 profit in FY 2025)Full year 2026 results: kr1.36 loss per share (down from kr0.62 profit in FY 2025). Revenue: kr16.7b (down 7.2% from FY 2025). Net loss: kr519.0m (down 319% from profit in FY 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.お知らせ • May 28+ 2 more updatesElekta AB (publ) Provides Earnings Guidance for the Fiscal Year 2026/2027Elekta AB (publ) provided earnings guidance for the fiscal year 2026/2027. For the year, The company expects net sales in constant currency to increase year over year, with an improvement in the EBIT margin.Board Change • May 21High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jan De Witte was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026お知らせ • Mar 05+ 1 more updateElekta AB (publ) to Report Q2, 2027 Results on Nov 25, 2026Elekta AB (publ) announced that they will report Q2, 2027 results on Nov 25, 2026お知らせ • Feb 26Elekta AB (publ), Annual General Meeting, Sep 03, 2026Elekta AB (publ), Annual General Meeting, Sep 03, 2026.お知らせ • Jan 23Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.お知らせ • Jan 16Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear AcceleratorElekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.お知らせ • Sep 04+ 1 more updateElekta AB (Publ) Elects Jan De Witte as DirectorElekta AB (publ) at its AGM held on September 4, 2025 approved to elect Jan De Witte, as Director for the period until the end of the next Annual General Meeting.お知らせ • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.お知らせ • May 29Elekta AB (publ), Annual General Meeting, Sep 04, 2025Elekta AB (publ), Annual General Meeting, Sep 04, 2025.お知らせ • May 28+ 1 more updateElekta AB (publ) Proposes Dividend for the Fiscal Year 2024/25The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.40) per share (paid in two installments) for 2024/25 amounting to SEK 917 million.お知らせ • May 19+ 1 more updateElekta AB (publ) to Report Q3, 2026 Results on Mar 05, 2026Elekta AB (publ) announced that they will report Q3, 2026 results on Mar 05, 2026お知らせ • May 05Elekta Announces Use of Its 1.5T Elekta Unity MR-LinacElekta announced that use of its 1.5T Elekta Unity MR-Linac can enable doctors to reduce the radiation dose to key structures responsible for erection among men being treated for prostate cancer. The preliminary results of the ERECT (EREctile Function Preservation for Prostate Cancer Radiation Therapy) trial were presented by University Medical Center Utrecht (UMC Utrecht, the Netherlands) clinicians at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual congress, May 2-6 in Vienna, Austria. The ERECT Trial is a sub-study of MOMENTUM, the MR-Linac Consortium's platform registry. It showed reduced incidence of erectile dysfunction (ED) and preserved erectile function up to 18 months using MR-guided radiotherapy (MRgRT) compared to conventional radiotherapy in patients with localized prostate cancer. In the study, researchers used Elekta Unity MR- Linac to treat 70 intermediate risk prostate cancer patients with a radiation dose of 36.25 Gy over five fractions. According to UMC Utrecht radiation oncologist and trial principal investor, Jochem van der Voort van Zyp, MD, PhD, Unity's pristine MR image quality not only enabled detailed visualization of the prostate, but also that of critical structures needed to achieve and maintain an erection. This anatomy includes the neurovascular bundle, internal pudendal arteries, corpora cavernosa and penile bulb. The endpoint of this preliminary analysis was the incidence of ED - as reported by patients - at six, 12- and 18-months post-treatment, compared to a control group that received the same dosage without neurovascular sparing. ED incidence was significantly lower in ERECT patients at all time points (six months: 6% vs. 21%, 12 months: 8.5% vs. 38%, 18 months: 16% vs. 36%). MRI is the gold standard for visualizing the prostate and surrounding structures in diagnostic radiology. Elekta Unity MR-Liac is the world's first and only device to combine a high-field MRI with a linear accelerator and enables clinicians to use MRI to guide radiation delivery to tumor targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If for example, if a prostate shifts due to motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues.お知らせ • Feb 27+ 1 more updateElekta AB (Publ) Announces Management ChangesElekta AB (publ) announced that Gustaf Salford, President and the Board of Directors, have decided that Gustaf will leave Elekta as of March 6, 2025. The Board of Directors has appointed Jonas Bolander, who has 23 years' experience at Elekta, as Acting President.Declared Dividend • Dec 30First half dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th March 2025 Payment date: 12th March 2025 Dividend yield will be 25%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio) nor is it covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 1.7% to bring the payout ratio under control. EPS is expected to grow by 79% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.お知らせ • Nov 27+ 2 more updatesElekta AB (publ) to Report Q2, 2026 Results on Nov 26, 2025Elekta AB (publ) announced that they will report Q2, 2026 results on Nov 26, 2025お知らせ • Nov 01Caroline Leksell Cooke Steps Down from Elekta AB's Board of DirectorsElekta AB announced that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member.お知らせ • Sep 27Elekta AB Submits Elekta Evo to U.S. FDA for Premarket ApprovalElekta AB announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) - this, less than a week after Evo received CE mark for sales and marketing in the European Union.Declared Dividend • Sep 08Dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th March 2025 Payment date: 12th March 2025 Dividend yield will be 24%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (81% earnings payout ratio) but not covered by cash flows (111% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 63% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Sep 06Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, RespectivelyElekta AB (publ) at its AGM held on September 5, 2024, approved dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is September 9, 2024. The second record day is March 7, 2025. The dividend is expected to be paid out on September 12, 2024, and on March 12, 2025, respectively.Upcoming Dividend • Aug 30Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 06 September 2024. Payment date: 12 September 2024. Payout ratio is on the higher end at 81%, and the cash payout ratio is above 100%. Trailing yield: 3.5%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.8%).Reported Earnings • Aug 29First quarter 2025 earnings released: EPS: kr0.18 (vs kr0.62 in 1Q 2024)First quarter 2025 results: EPS: kr0.18 (down from kr0.62 in 1Q 2024). Revenue: kr3.83b (flat on 1Q 2024). Net income: kr70.0m (down 71% from 1Q 2024). Profit margin: 1.8% (down from 6.2% in 1Q 2024). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (112% cash payout ratio). Share price has been volatile over the past 3 months (7.0% average weekly change).Declared Dividend • Aug 04Dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th September 2024 Payment date: 12th September 2024 Dividend yield will be 26%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (70% earnings payout ratio) but not covered by cash flows (112% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 50% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jul 07Full year 2024 earnings released: EPS: kr3.41 (vs kr2.47 in FY 2023)Full year 2024 results: EPS: kr3.41 (up from kr2.47 in FY 2023). Revenue: kr18.1b (up 7.4% from FY 2023). Net income: kr1.30b (up 38% from FY 2023). Profit margin: 7.2% (up from 5.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • Jul 06Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025Elekta AB (publ) announced that they will report Q4, 2025 results on May 28, 2025Recent Insider Transactions • Jun 11President & CEO recently bought €42k worth of stockOn the 7th of June, Gustaf Salford bought around 7k shares on-market at roughly €5.98 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Gustaf has been a buyer over the last 12 months, purchasing a net total of €84k worth in shares.お知らせ • Jun 06Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025Elekta AB (publ) announced that they will report Q3, 2025 results on Feb 21, 2025Reported Earnings • Jun 06Full year 2024 earnings released: EPS: kr3.41 (vs kr2.47 in FY 2023)Full year 2024 results: EPS: kr3.41 (up from kr2.47 in FY 2023). Revenue: kr18.1b (up 7.4% from FY 2023). Net income: kr1.30b (up 38% from FY 2023). Profit margin: 7.2% (up from 5.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.お知らせ • Mar 02Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the BoardElekta AB announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective March 1, 2024. Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta’s Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role.Reported Earnings • Mar 01Third quarter 2024 earnings released: EPS: kr0.80 (vs kr0.56 in 3Q 2023)Third quarter 2024 results: EPS: kr0.80 (up from kr0.56 in 3Q 2023). Revenue: kr4.54b (up 4.6% from 3Q 2023). Net income: kr305.0m (up 41% from 3Q 2023). Profit margin: 6.7% (up from 5.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 29Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024Elekta AB (publ) announced that they will report Q2, 2025 results on Nov 27, 2024Upcoming Dividend • Feb 19Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 26 February 2024. Payment date: 01 March 2024. Payout ratio is a comfortable 68% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (1.6%).Reported Earnings • Dec 01Second quarter 2024 earnings released: EPS: kr0.90 (vs kr0.32 in 2Q 2023)Second quarter 2024 results: EPS: kr0.90 (up from kr0.32 in 2Q 2023). Revenue: kr4.73b (up 16% from 2Q 2023). Net income: kr344.0m (up 182% from 2Q 2023). Profit margin: 7.3% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 30+ 1 more updateElekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024Elekta AB (publ) announced that they will report fiscal year 2024 final results on Jul 05, 2024お知らせ • Nov 01Elekta AB (publ) Announces Composition of Nomination CommitteeElekta AB (publ) announced that Annual General Meeting on August 24, 2023, the Chairman of the Board has convened the Nomination Committee for the 2024 Annual General Meeting by contacting the company's shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2020 Annual General Meeting. The Nomination Committee consists of: Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties' holdings; Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund; Katarina Hammar, appointed by Nordea Funds; Patrik Jönsson, appointed by SEB Funds; Jesper Bergström, appointed by Handelsbanken Funds.お知らせ • Oct 24Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD) on October 23, 2023. The intention is to complete the transaction during the second quarter of Elekta’s fiscal year 2023/24.お知らせ • Oct 13Elekta AB (publ), Annual General Meeting, Sep 05, 2024Elekta AB (publ), Annual General Meeting, Sep 05, 2024.Recent Insider Transactions • Sep 23Founder & Chairman recently sold €5.1m worth of stockOn the 20th of September, Laurent Leksell sold around 800k shares on-market at roughly €6.33 per share. This transaction amounted to 9.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Laurent's only on-market trade for the last 12 months.Reported Earnings • Aug 25First quarter 2024 earnings released: EPS: kr0.62 (vs kr0.16 in 1Q 2023)First quarter 2024 results: EPS: kr0.62 (up from kr0.16 in 1Q 2023). Revenue: kr3.83b (up 15% from 1Q 2023). Net income: kr238.0m (up 297% from 1Q 2023). Profit margin: 6.2% (up from 1.8% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 15% per year.お知らせ • Aug 25+ 1 more updateElekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, RespectivelyElekta AB (publ) announced that at its AGM held on 24 August 2023, the Meeting resolved on a dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is 28 August, 2023. The second record day is 27 February, 2024. The dividend is expected to be paid out on 31 August, 2023 and on 1 March, 2024 respectively.Upcoming Dividend • Aug 18Upcoming dividend of kr1.20 per share at 3.1% yieldEligible shareholders must have bought the stock before 25 August 2023. Payment date: 31 August 2023. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.0%).Reported Earnings • Jul 09Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)Full year 2023 results: EPS: kr2.47 (down from kr3.02 in FY 2022). Revenue: kr16.9b (up 16% from FY 2022). Net income: kr943.0m (down 18% from FY 2022). Profit margin: 5.6% (down from 7.9% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year.お知らせ • Jun 30Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ)Elekta AB (publ) announced that 2023 Annual General Meeting to held on 24 August 2023, Johan Malmquist has declined re-election as director of the company.Buying Opportunity • May 31Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.8%. The fair value is estimated to be €8.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has declined by 11%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings is also forecast to grow by 23% per annum over the same time period.お知らせ • May 26+ 2 more updatesElekta AB (publ) to Report Q3, 2024 Results on Feb 09, 2024Elekta AB (publ) announced that they will report Q3, 2024 results on Feb 09, 2024Reported Earnings • May 26Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)Full year 2023 results: EPS: kr2.47 (down from kr3.02 in FY 2022). Revenue: kr16.9b (up 16% from FY 2022). Net income: kr943.0m (down 18% from FY 2022). Profit margin: 5.6% (down from 7.9% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year.お知らせ • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.お知らせ • May 13Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONEElekta AB (publ) is excited to announced the launch of the first phase of Elekta ONE, its most comprehensive and advanced software portfolio for oncology departments and clinics, including radiation therapy planning, comprehensive treatment management, and delivery. It brings all Elekta software products, solutions and services under one umbrella providing all users with one unified software experience. Previously, many cancer clinics have wrestled with stand-alone, closed systems, each with a different purpose. The result has been an unfavorable user experience and steep learning curve, adding pressure to an already strained resource: the clinical team. Elekta ONE aims to improve efficiency in the clinic by as much as 50%, eventually through smarter workflows, increased automation, and by learning from every patient treated. Its workflow-driven approach and deep integration between applications allows information to flow freely, giving clinicians a seamless user experience.Buying Opportunity • May 09Now 21% undervaluedOver the last 90 days, the stock is up 13%. The fair value is estimated to be €9.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 7.4% per annum. Earnings is also forecast to grow by 23% per annum over the same time period.Reported Earnings • Feb 26Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr4.34b (up 20% from 3Q 2022). Net income: kr216.0m (down 5.7% from 3Q 2022). Profit margin: 5.0% (down from 6.4% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year.Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €7.73, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.31 per share.Upcoming Dividend • Feb 17Upcoming dividend of kr1.20 per share at 3.1% yieldEligible shareholders must have bought the stock before 24 February 2023. Payment date: 02 March 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.7%).お知らせ • Feb 14Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter on February 13, 2023. The first quarter of Elekta’s fiscal year 2023-2024.お知らせ • Dec 13First Ever Patient Treated for Pancreatic Cancer with New Advanced Radiotherapy Motion Management Using Elekta Unity MR-LinacElekta AB (publ) announced that UTRECHT - A milestone was reached in radiation therapy last week as the first patients completed their full course of radiation therapy treatment with Elekta (EKTA-B.ST) Unity MR-Linac using Comprehensive Motion Management (CMM) with True Tracking and automatic gating functionalities. A patient with pancreatic cancer was treated at University Medical Center (UMC) Utrecht using Unity's CMM developments, which can continuously calculate the movement of the tumor and correct for it automatically. This first ever treatment delivery using CMM went smoothly and did not increase the total treatment time per fraction. The beam wasautomatically turned on when the patient was in the exhale phase of breathing, so they were not required to hold their breath for extended periods, according to Dr. Martijn Intven, a radiation oncologist at UMC Utrecht. With automatic gating, supported by Elekta's unique True Tracking algorithms, the radiation beam is automatically turned off when the tumor moves outside of the beam, ensuring treatment is always focused on the target. For the first time ever in radiotherapy, Elekta Unity's True Tracking provides continuous tracking of the 3D position of a target anywhere in the body, non-invasively and without surrogates. In addition, CMM offers rapid compensation for sustained intrafraction drift: realigning the beam with the new position of the target without the need to re-acquire a 3D image. UMC Utrecht was Elekta's initial research partner in the development of Elekta Unity, aproject that has extended over two decades. During this time, clinicians at UMC have helped pioneer radiation treatment that responds to movement of tumors during delivery.Reported Earnings • Nov 25Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr4.08b (up 10% from 2Q 2022). Net income: kr122.0m (down 68% from 2Q 2022). Profit margin: 3.0% (down from 10% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 24Elekta AB (publ), Annual General Meeting, Aug 24, 2023Elekta AB (publ), Annual General Meeting, Aug 24, 2023.お知らせ • Nov 18Swedish and Jordanian Royalty Inaugurate Elekta AB (publ) Radiation Therapy Devices for Cancer and Brain DiseaseDignitaries from Sweden and Jordan attended the inauguration of two of Elekta's cancer care technologies, including an advanced linear accelerator used to deliver radiation to treat people with cancer and a Leksell Gamma Knife radiosurgery system, which is used to treat a range of neurosurgical and oncological brain indications. The ceremony was held on November 16 at King Hussein Cancer Center together with King Hussein Cancer Foundation in Amman. Representing Elekta, Caroline Leksell Cooke, Member of Elekta's Board of Directors and granddaughter of Professor Lars Leksell, inventor of the Gamma Knife, spoke of her pride in the company's collaboration with health care facilities in Jordan and support to improve the lives of some of the 11,500 people diagnosed with cancer each year. The first Elekta linac and Gamma Knife were installed in Jordan in 2005, with successive upgrades and new technology since. Today, a wide spectrum of cancer is managed with the country's 15 Elekta linacs, two Gamma Knife systems, and brachytherapy solutions. Their Majesties the King and Queen of Sweden, Her Royal Highness Princess Ghida Talal, who is Chairperson of KHCC, His Royal Highness Prince Talal bin Muhammad, Caroline Leksell Cooke, the Swedish Ambassador to Jordan H.E. Alexandra Rydmark, and Dr. Asem Mansour KHCC General Director, were among those attending the event. The inauguration ceremony was part of a three-day state visit by Sweden's King Carl XVI Gustaf and Queen Silvia, together with Sweden's Minister of Foreign Affairs, H.E.Tobias Billström. During their visit, they will also pay tribute to the 40th anniversary of Sweden's diplomatic presence in Jordan.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Director Kelly Londy was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 28Elekta AB (publ) Announces Elekta Esprit Receives FDA 510(k) ClearanceElekta AB (publ) announced that Elekta Esprit, a new Leksell Gamma Knife® radiosurgery platform, received FDA 510(k) clearance. This milestone makes the system available to clinicians and people with brain disease in the U.S., as well as opening the door to other countries where FDA approval is recognized. Leksell Gamma Knife has been designed as a gentler alternative to open surgery and conventional radiotherapy. It can target the smallest and most challenging intracranial tumors and lesions with minimal effect on healthy tissue. This vital precision safeguards motor, sensory and neurocognitive function to help protect the mind and the person. With a variety of innovations now available in a single platform, Esprit continues to offer clinicians the option of frameless or frame-based workflows with a frame that provides superior visualization. Remote accessibility and collaboration tools for the treatment team are designed to meet the needs of changing environments. Esprit provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery. Leksell Gamma Knife has over 50 years of clinical evidence and remains the gold standard of intracranial radiosurgery. The U.S. has the largest installed base of Gamma Knife systems, whose users have contributed to driving the standard of care forward. Continuous advances in its design have resulted in extremely fast automated treatment planning for clinicians, and Esprit is ideal for safely treating a broad range of indications, including multiple metastases, arteriovenous malformations, trigeminal neuralgia and vestibular schwannoma.お知らせ • Oct 26Elekta Unity Demonstrates Promising Quality of Life Outcomes for Pancreas and Prostate Cancers At Astro Annual MeetingElekta announced two new reports from the MOMENTUM Study highlighting the clinical impact of Elekta Unity MR-Linac in treating pancreas and prostate cancers. The abstracts were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, in San Antonio, Texas. These reports add to a growing body of evidence showing that enhanced precision radiotherapy using MR-guided on-line adaptation may improve outcomes in both pancreas and prostate cancers, two common treatment indications for radiotherapy. Elekta Unity is the world’s first and only MR-Linac to unite diagnostic quality high field (1.5T) MRI with a linear accelerator to deliver unprecedented visibility and precision, thus enabling personalized radiotherapy. The MOMENTUM Study is the largest prospective international registry of high field MR-guided therapy, currently enrolling patients from 15 major cancer centers in North America, Europe and Australia. In the study of pancreas tumors, which are historically treatment resistant, 80 patients treated with an ablative radiation dose using MR-guided online adaption were enrolled and surveyed using standardized quality-of-life questionnaires. Patients reported limited adverse effects and stable global health status out to three months. Importantly, 67% of patients were alive one year after the end of treatment. In the study of prostate cancers, 218 patients were enrolled and followed with standardized quality-of-life questionnaires. Approximately half of the patients were treated using both MR-guidance and on-line adaptation functionality on Elekta Unity while the remaining half were treated using only MR-guidance without on-line adaptation. As expected, investigators observed a decline in quality-of-life scores three months after the end of treatment in the cohort treated with MR-guidance alone. However, no significant decline in quality of life was observed in the cohort of prostate cancers treated using both MR-guidance and on-line adaptation.お知らせ • Sep 19Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD)Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD)お知らせ • Aug 26+ 1 more updateElekta AB (publ) Elects Kelly Londy as a DirectorElekta AB (publ) announced that Kelly Londy was elected as a new Director at its Annual General Meeting held on 25 August 2022.Reported Earnings • Aug 26First quarter 2023 earnings released: EPS: kr0.16 (vs kr0.33 in 1Q 2022)First quarter 2023 results: EPS: kr0.16 (down from kr0.33 in 1Q 2022). Revenue: kr3.33b (up 11% from 1Q 2022). Net income: kr60.0m (down 53% from 1Q 2022). Profit margin: 1.8% (down from 4.2% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.5%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany.Upcoming Dividend • Aug 19Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 26 August 2022. Payment date: 01 September 2022. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.2%).Reported Earnings • Jul 13Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021)Full year 2022 results: EPS: kr3.02 (down from kr3.28 in FY 2021). Revenue: kr14.5b (up 5.7% from FY 2021). Net income: kr1.15b (down 8.0% from FY 2021). Profit margin: 7.9% (down from 9.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 9.4%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.お知らせ • Jul 09+ 1 more updateElekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023Elekta AB (publ) announced that they will report fiscal year 2023 results on May 25, 2023Reported Earnings • May 26Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021)Full year 2022 results: EPS: kr3.02 (down from kr3.28 in FY 2021). Revenue: kr14.5b (up 5.7% from FY 2021). Net income: kr1.15b (down 8.0% from FY 2021). Profit margin: 7.9% (down from 9.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.4%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • May 26Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021/22The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.20) per share (paid in two installments) for the fiscal year 2021/22.お知らせ • May 08Elekta Launches New Radiosurgery System: Elekta EspritElekta AB (publ) has evolved radiosurgery to an unprecedented level with the launch of Elekta Esprit. This latest and most advanced system will offer significantly faster automated treatment planning for clinicians, more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person. With a variety of innovations now available in a single platform, Esprit offers clinicians superior visualization, as well as remote accessibility and collaboration tools for the treatment team. And it provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Director Cecilia Wikström was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 26+ 2 more updatesElekta AB (publ) to Report Fiscal Year 2022 Final Results on Jul 08, 2022Elekta AB (publ) announced that they will report fiscal year 2022 final results on Jul 08, 2022Recent Insider Transactions • Mar 10President of Brachy Solutions recently bought €30k worth of stockOn the 2nd of March, John Lapré bought around 4k shares on-market at roughly €7.41 per share. In the last 3 months, there was an even bigger purchase from another insider worth €145k. Insiders have collectively bought €2.1m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Mar 04Insider recently bought €49k worth of stockOn the 24th of February, Verena Schiller bought around 6k shares on-market at roughly €7.58 per share. In the last 3 months, there was an even bigger purchase from another insider worth €145k. Insiders have collectively bought €2.1m more in shares than they have sold in the last 12 months.Reported Earnings • Feb 25Third quarter 2022 earnings: Revenues in line with analyst expectationsThird quarter 2022 results: Revenue: kr3.60b (flat on 3Q 2021). Net income: kr229.0m (down 29% from 3Q 2021). Profit margin: 6.4% (down from 9.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Feb 24Elekta AB (publ), Annual General Meeting, Aug 25, 2022Elekta AB (publ), Annual General Meeting, Aug 25, 2022.Valuation Update With 7 Day Price Move • Feb 19Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €7.79, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 29x in the Medical Equipment industry in Germany. Total loss to shareholders of 32% over the past three years.Upcoming Dividend • Feb 18Upcoming dividend of kr1.10 per shareEligible shareholders must have bought the stock before 25 February 2022. Payment date: 03 March 2022. Payout ratio is a comfortable 72% and the cash payout ratio is 80%. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (3.3%). Higher than average of industry peers (1.1%).株主還元EJXBDE Medical EquipmentDE 市場7D5.3%1.5%1.7%1Y4.2%-26.8%2.6%株主還元を見る業界別リターン: EJXB過去 1 年間で-26.8 % の収益を上げたGerman Medical Equipment業界を上回りました。リターン対市場: EJXB過去 1 年間で2.6 % の収益を上げたGerman市場を上回りました。価格変動Is EJXB's price volatile compared to industry and market?EJXB volatilityEJXB Average Weekly Movement6.0%Medical Equipment Industry Average Movement5.9%Market Average Movement5.6%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%安定した株価: EJXB 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: EJXBの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19724,353Jakob Just-Bomholtwww.elekta.comElekta AB (publish)は医療技術会社で、がんおよび脳疾患の治療のための臨床ソリューションの提供を世界中で行っている。同社は、リアルタイムMR可視化用Elekta Unity、脳転移ソリューションElekta Versa HD、リニアックElekta Harmony、単純から複雑な放射線治療を必要とする様々な患者の治療用Elekta Infinity、品質保証、治療および動作管理ソリューションなどの放射線治療製品を提供している。また、定位放射線手術製品として、Elekta Esprit、個別化放射線治療用Leksell Gamma Knife Icon、放射線外科医用ツールLeksell Gamma Knife Perfexion、治療計画・管理ソフトウェアLeksell GammaPlanを提供している。さらに、同社は複数のエレクタソリューションのソフトウェアスイートであるElekta ONEを提供している。さらに、画像ガイド下ブラキセラピーソリューション「Elekta Studio」、モバイルCTスキャナー「ImagingRing」、反復作業を容易にするスマートツール「Oncentra Brachy」、電子ブラキセラピーシステム「Elekta Xoft Axxent」、子宮頸がん患者用アプリケーター「Elekta Geneva」、ワークフローのすべてのステップを正確に実行できるアフターローダー「Elekta Flexitron」、腫瘍医が局所進行子宮頸がんを治療できるアプリケーター「Venezia」などのブラキセラピー製品を提供している。さらに、同社は頭蓋内神経外科手術用のLeksell Vantage Stereotactic Systemなどの神経外科製品を提供している。さらに、個別化がん治療のためのElekta Kaikuや動物用放射線治療ソリューションも提供している。同社は1972年に設立され、スウェーデンのストックホルムに本社を置いている。もっと見るElekta AB (publ) 基礎のまとめElekta の収益と売上を時価総額と比較するとどうか。EJXB 基礎統計学時価総額€1.79b収益（TTM）-€46.93m売上高(TTM)€1.51b1.2xP/Sレシオ-38.1xPER（株価収益率EJXB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計EJXB 損益計算書（TTM）収益SEK 16.72b売上原価SEK 10.30b売上総利益SEK 6.42bその他の費用SEK 6.94b収益-SEK 519.00m直近の収益報告Apr 30, 2026次回決算日Jul 03, 2026一株当たり利益（EPS）-1.36グロス・マージン38.38%純利益率-3.10%有利子負債／自己資本比率88.4%EJXB の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.6%現在の配当利回り-177%配当性向EJXB 配当は確実ですか？EJXB 配当履歴とベンチマークを見るEJXB 、いつまでに購入すれば配当金を受け取れますか？Elekta 配当日配当落ち日Sep 04 2026配当支払日Sep 10 2026配当落ちまでの日数62 days配当支払日までの日数68 daysEJXB 配当は確実ですか？EJXB 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/02 12:20終値2026/07/02 00:00収益2026/04/30年間収益2026/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Elekta AB (publ) 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27 アナリスト機関null nullABG Sundal CollierAlexander KlebanBarclaysSally TaylorBarclays24 その他のアナリストを表示
Recent Insider Transactions • Jul 01Chief Product & Technology Officer recently bought €98k worth of stockOn the 26th of June, Christopher Busch bought around 23k shares on-market at roughly €4.27 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €373k more in shares than they have sold in the last 12 months.
Declared Dividend • May 31Final dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 4th September 2026 Payment date: 10th September 2026 Dividend yield will be 27%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (66% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time.
Reported Earnings • May 28Full year 2026 earnings released: kr1.36 loss per share (vs kr0.62 profit in FY 2025)Full year 2026 results: kr1.36 loss per share (down from kr0.62 profit in FY 2025). Revenue: kr16.7b (down 7.2% from FY 2025). Net loss: kr519.0m (down 319% from profit in FY 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.
お知らせ • May 28+ 2 more updatesElekta AB (publ) Provides Earnings Guidance for the Fiscal Year 2026/2027Elekta AB (publ) provided earnings guidance for the fiscal year 2026/2027. For the year, The company expects net sales in constant currency to increase year over year, with an improvement in the EBIT margin.
Board Change • May 21High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jan De Witte was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026
Recent Insider Transactions • Jul 01Chief Product & Technology Officer recently bought €98k worth of stockOn the 26th of June, Christopher Busch bought around 23k shares on-market at roughly €4.27 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €373k more in shares than they have sold in the last 12 months.
Declared Dividend • May 31Final dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 4th September 2026 Payment date: 10th September 2026 Dividend yield will be 27%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (66% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time.
Reported Earnings • May 28Full year 2026 earnings released: kr1.36 loss per share (vs kr0.62 profit in FY 2025)Full year 2026 results: kr1.36 loss per share (down from kr0.62 profit in FY 2025). Revenue: kr16.7b (down 7.2% from FY 2025). Net loss: kr519.0m (down 319% from profit in FY 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.
お知らせ • May 28+ 2 more updatesElekta AB (publ) Provides Earnings Guidance for the Fiscal Year 2026/2027Elekta AB (publ) provided earnings guidance for the fiscal year 2026/2027. For the year, The company expects net sales in constant currency to increase year over year, with an improvement in the EBIT margin.
Board Change • May 21High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jan De Witte was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026
お知らせ • Mar 05+ 1 more updateElekta AB (publ) to Report Q2, 2027 Results on Nov 25, 2026Elekta AB (publ) announced that they will report Q2, 2027 results on Nov 25, 2026
お知らせ • Feb 26Elekta AB (publ), Annual General Meeting, Sep 03, 2026Elekta AB (publ), Annual General Meeting, Sep 03, 2026.
お知らせ • Jan 23Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.
お知らせ • Jan 16Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear AcceleratorElekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.
お知らせ • Sep 04+ 1 more updateElekta AB (Publ) Elects Jan De Witte as DirectorElekta AB (publ) at its AGM held on September 4, 2025 approved to elect Jan De Witte, as Director for the period until the end of the next Annual General Meeting.
お知らせ • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.
お知らせ • May 29Elekta AB (publ), Annual General Meeting, Sep 04, 2025Elekta AB (publ), Annual General Meeting, Sep 04, 2025.
お知らせ • May 28+ 1 more updateElekta AB (publ) Proposes Dividend for the Fiscal Year 2024/25The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.40) per share (paid in two installments) for 2024/25 amounting to SEK 917 million.
お知らせ • May 19+ 1 more updateElekta AB (publ) to Report Q3, 2026 Results on Mar 05, 2026Elekta AB (publ) announced that they will report Q3, 2026 results on Mar 05, 2026
お知らせ • May 05Elekta Announces Use of Its 1.5T Elekta Unity MR-LinacElekta announced that use of its 1.5T Elekta Unity MR-Linac can enable doctors to reduce the radiation dose to key structures responsible for erection among men being treated for prostate cancer. The preliminary results of the ERECT (EREctile Function Preservation for Prostate Cancer Radiation Therapy) trial were presented by University Medical Center Utrecht (UMC Utrecht, the Netherlands) clinicians at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual congress, May 2-6 in Vienna, Austria. The ERECT Trial is a sub-study of MOMENTUM, the MR-Linac Consortium's platform registry. It showed reduced incidence of erectile dysfunction (ED) and preserved erectile function up to 18 months using MR-guided radiotherapy (MRgRT) compared to conventional radiotherapy in patients with localized prostate cancer. In the study, researchers used Elekta Unity MR- Linac to treat 70 intermediate risk prostate cancer patients with a radiation dose of 36.25 Gy over five fractions. According to UMC Utrecht radiation oncologist and trial principal investor, Jochem van der Voort van Zyp, MD, PhD, Unity's pristine MR image quality not only enabled detailed visualization of the prostate, but also that of critical structures needed to achieve and maintain an erection. This anatomy includes the neurovascular bundle, internal pudendal arteries, corpora cavernosa and penile bulb. The endpoint of this preliminary analysis was the incidence of ED - as reported by patients - at six, 12- and 18-months post-treatment, compared to a control group that received the same dosage without neurovascular sparing. ED incidence was significantly lower in ERECT patients at all time points (six months: 6% vs. 21%, 12 months: 8.5% vs. 38%, 18 months: 16% vs. 36%). MRI is the gold standard for visualizing the prostate and surrounding structures in diagnostic radiology. Elekta Unity MR-Liac is the world's first and only device to combine a high-field MRI with a linear accelerator and enables clinicians to use MRI to guide radiation delivery to tumor targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If for example, if a prostate shifts due to motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues.
お知らせ • Feb 27+ 1 more updateElekta AB (Publ) Announces Management ChangesElekta AB (publ) announced that Gustaf Salford, President and the Board of Directors, have decided that Gustaf will leave Elekta as of March 6, 2025. The Board of Directors has appointed Jonas Bolander, who has 23 years' experience at Elekta, as Acting President.
Declared Dividend • Dec 30First half dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th March 2025 Payment date: 12th March 2025 Dividend yield will be 25%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio) nor is it covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 1.7% to bring the payout ratio under control. EPS is expected to grow by 79% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.
お知らせ • Nov 27+ 2 more updatesElekta AB (publ) to Report Q2, 2026 Results on Nov 26, 2025Elekta AB (publ) announced that they will report Q2, 2026 results on Nov 26, 2025
お知らせ • Nov 01Caroline Leksell Cooke Steps Down from Elekta AB's Board of DirectorsElekta AB announced that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member.
お知らせ • Sep 27Elekta AB Submits Elekta Evo to U.S. FDA for Premarket ApprovalElekta AB announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) - this, less than a week after Evo received CE mark for sales and marketing in the European Union.
Declared Dividend • Sep 08Dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th March 2025 Payment date: 12th March 2025 Dividend yield will be 24%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (81% earnings payout ratio) but not covered by cash flows (111% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 63% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Sep 06Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, RespectivelyElekta AB (publ) at its AGM held on September 5, 2024, approved dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is September 9, 2024. The second record day is March 7, 2025. The dividend is expected to be paid out on September 12, 2024, and on March 12, 2025, respectively.
Upcoming Dividend • Aug 30Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 06 September 2024. Payment date: 12 September 2024. Payout ratio is on the higher end at 81%, and the cash payout ratio is above 100%. Trailing yield: 3.5%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.8%).
Reported Earnings • Aug 29First quarter 2025 earnings released: EPS: kr0.18 (vs kr0.62 in 1Q 2024)First quarter 2025 results: EPS: kr0.18 (down from kr0.62 in 1Q 2024). Revenue: kr3.83b (flat on 1Q 2024). Net income: kr70.0m (down 71% from 1Q 2024). Profit margin: 1.8% (down from 6.2% in 1Q 2024). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (112% cash payout ratio). Share price has been volatile over the past 3 months (7.0% average weekly change).
Declared Dividend • Aug 04Dividend of kr1.20 announcedShareholders will receive a dividend of kr1.20. Ex-date: 6th September 2024 Payment date: 12th September 2024 Dividend yield will be 26%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (70% earnings payout ratio) but not covered by cash flows (112% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 50% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jul 07Full year 2024 earnings released: EPS: kr3.41 (vs kr2.47 in FY 2023)Full year 2024 results: EPS: kr3.41 (up from kr2.47 in FY 2023). Revenue: kr18.1b (up 7.4% from FY 2023). Net income: kr1.30b (up 38% from FY 2023). Profit margin: 7.2% (up from 5.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • Jul 06Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025Elekta AB (publ) announced that they will report Q4, 2025 results on May 28, 2025
Recent Insider Transactions • Jun 11President & CEO recently bought €42k worth of stockOn the 7th of June, Gustaf Salford bought around 7k shares on-market at roughly €5.98 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Gustaf has been a buyer over the last 12 months, purchasing a net total of €84k worth in shares.
お知らせ • Jun 06Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025Elekta AB (publ) announced that they will report Q3, 2025 results on Feb 21, 2025
Reported Earnings • Jun 06Full year 2024 earnings released: EPS: kr3.41 (vs kr2.47 in FY 2023)Full year 2024 results: EPS: kr3.41 (up from kr2.47 in FY 2023). Revenue: kr18.1b (up 7.4% from FY 2023). Net income: kr1.30b (up 38% from FY 2023). Profit margin: 7.2% (up from 5.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
お知らせ • Mar 02Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the BoardElekta AB announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective March 1, 2024. Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta’s Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role.
Reported Earnings • Mar 01Third quarter 2024 earnings released: EPS: kr0.80 (vs kr0.56 in 3Q 2023)Third quarter 2024 results: EPS: kr0.80 (up from kr0.56 in 3Q 2023). Revenue: kr4.54b (up 4.6% from 3Q 2023). Net income: kr305.0m (up 41% from 3Q 2023). Profit margin: 6.7% (up from 5.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 29Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024Elekta AB (publ) announced that they will report Q2, 2025 results on Nov 27, 2024
Upcoming Dividend • Feb 19Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 26 February 2024. Payment date: 01 March 2024. Payout ratio is a comfortable 68% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (1.6%).
Reported Earnings • Dec 01Second quarter 2024 earnings released: EPS: kr0.90 (vs kr0.32 in 2Q 2023)Second quarter 2024 results: EPS: kr0.90 (up from kr0.32 in 2Q 2023). Revenue: kr4.73b (up 16% from 2Q 2023). Net income: kr344.0m (up 182% from 2Q 2023). Profit margin: 7.3% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 30+ 1 more updateElekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024Elekta AB (publ) announced that they will report fiscal year 2024 final results on Jul 05, 2024
お知らせ • Nov 01Elekta AB (publ) Announces Composition of Nomination CommitteeElekta AB (publ) announced that Annual General Meeting on August 24, 2023, the Chairman of the Board has convened the Nomination Committee for the 2024 Annual General Meeting by contacting the company's shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2020 Annual General Meeting. The Nomination Committee consists of: Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties' holdings; Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund; Katarina Hammar, appointed by Nordea Funds; Patrik Jönsson, appointed by SEB Funds; Jesper Bergström, appointed by Handelsbanken Funds.
お知らせ • Oct 24Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD) on October 23, 2023. The intention is to complete the transaction during the second quarter of Elekta’s fiscal year 2023/24.
お知らせ • Oct 13Elekta AB (publ), Annual General Meeting, Sep 05, 2024Elekta AB (publ), Annual General Meeting, Sep 05, 2024.
Recent Insider Transactions • Sep 23Founder & Chairman recently sold €5.1m worth of stockOn the 20th of September, Laurent Leksell sold around 800k shares on-market at roughly €6.33 per share. This transaction amounted to 9.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Laurent's only on-market trade for the last 12 months.
Reported Earnings • Aug 25First quarter 2024 earnings released: EPS: kr0.62 (vs kr0.16 in 1Q 2023)First quarter 2024 results: EPS: kr0.62 (up from kr0.16 in 1Q 2023). Revenue: kr3.83b (up 15% from 1Q 2023). Net income: kr238.0m (up 297% from 1Q 2023). Profit margin: 6.2% (up from 1.8% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 15% per year.
お知らせ • Aug 25+ 1 more updateElekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, RespectivelyElekta AB (publ) announced that at its AGM held on 24 August 2023, the Meeting resolved on a dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is 28 August, 2023. The second record day is 27 February, 2024. The dividend is expected to be paid out on 31 August, 2023 and on 1 March, 2024 respectively.
Upcoming Dividend • Aug 18Upcoming dividend of kr1.20 per share at 3.1% yieldEligible shareholders must have bought the stock before 25 August 2023. Payment date: 31 August 2023. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.0%).
Reported Earnings • Jul 09Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)Full year 2023 results: EPS: kr2.47 (down from kr3.02 in FY 2022). Revenue: kr16.9b (up 16% from FY 2022). Net income: kr943.0m (down 18% from FY 2022). Profit margin: 5.6% (down from 7.9% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year.
お知らせ • Jun 30Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ)Elekta AB (publ) announced that 2023 Annual General Meeting to held on 24 August 2023, Johan Malmquist has declined re-election as director of the company.
Buying Opportunity • May 31Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.8%. The fair value is estimated to be €8.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has declined by 11%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings is also forecast to grow by 23% per annum over the same time period.
お知らせ • May 26+ 2 more updatesElekta AB (publ) to Report Q3, 2024 Results on Feb 09, 2024Elekta AB (publ) announced that they will report Q3, 2024 results on Feb 09, 2024
Reported Earnings • May 26Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)Full year 2023 results: EPS: kr2.47 (down from kr3.02 in FY 2022). Revenue: kr16.9b (up 16% from FY 2022). Net income: kr943.0m (down 18% from FY 2022). Profit margin: 5.6% (down from 7.9% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year.
お知らせ • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.
お知らせ • May 13Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONEElekta AB (publ) is excited to announced the launch of the first phase of Elekta ONE, its most comprehensive and advanced software portfolio for oncology departments and clinics, including radiation therapy planning, comprehensive treatment management, and delivery. It brings all Elekta software products, solutions and services under one umbrella providing all users with one unified software experience. Previously, many cancer clinics have wrestled with stand-alone, closed systems, each with a different purpose. The result has been an unfavorable user experience and steep learning curve, adding pressure to an already strained resource: the clinical team. Elekta ONE aims to improve efficiency in the clinic by as much as 50%, eventually through smarter workflows, increased automation, and by learning from every patient treated. Its workflow-driven approach and deep integration between applications allows information to flow freely, giving clinicians a seamless user experience.
Buying Opportunity • May 09Now 21% undervaluedOver the last 90 days, the stock is up 13%. The fair value is estimated to be €9.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 7.4% per annum. Earnings is also forecast to grow by 23% per annum over the same time period.
Reported Earnings • Feb 26Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr4.34b (up 20% from 3Q 2022). Net income: kr216.0m (down 5.7% from 3Q 2022). Profit margin: 5.0% (down from 6.4% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year.
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €7.73, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.31 per share.
Upcoming Dividend • Feb 17Upcoming dividend of kr1.20 per share at 3.1% yieldEligible shareholders must have bought the stock before 24 February 2023. Payment date: 02 March 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.7%).
お知らせ • Feb 14Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter on February 13, 2023. The first quarter of Elekta’s fiscal year 2023-2024.
お知らせ • Dec 13First Ever Patient Treated for Pancreatic Cancer with New Advanced Radiotherapy Motion Management Using Elekta Unity MR-LinacElekta AB (publ) announced that UTRECHT - A milestone was reached in radiation therapy last week as the first patients completed their full course of radiation therapy treatment with Elekta (EKTA-B.ST) Unity MR-Linac using Comprehensive Motion Management (CMM) with True Tracking and automatic gating functionalities. A patient with pancreatic cancer was treated at University Medical Center (UMC) Utrecht using Unity's CMM developments, which can continuously calculate the movement of the tumor and correct for it automatically. This first ever treatment delivery using CMM went smoothly and did not increase the total treatment time per fraction. The beam wasautomatically turned on when the patient was in the exhale phase of breathing, so they were not required to hold their breath for extended periods, according to Dr. Martijn Intven, a radiation oncologist at UMC Utrecht. With automatic gating, supported by Elekta's unique True Tracking algorithms, the radiation beam is automatically turned off when the tumor moves outside of the beam, ensuring treatment is always focused on the target. For the first time ever in radiotherapy, Elekta Unity's True Tracking provides continuous tracking of the 3D position of a target anywhere in the body, non-invasively and without surrogates. In addition, CMM offers rapid compensation for sustained intrafraction drift: realigning the beam with the new position of the target without the need to re-acquire a 3D image. UMC Utrecht was Elekta's initial research partner in the development of Elekta Unity, aproject that has extended over two decades. During this time, clinicians at UMC have helped pioneer radiation treatment that responds to movement of tumors during delivery.
Reported Earnings • Nov 25Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr4.08b (up 10% from 2Q 2022). Net income: kr122.0m (down 68% from 2Q 2022). Profit margin: 3.0% (down from 10% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 24Elekta AB (publ), Annual General Meeting, Aug 24, 2023Elekta AB (publ), Annual General Meeting, Aug 24, 2023.
お知らせ • Nov 18Swedish and Jordanian Royalty Inaugurate Elekta AB (publ) Radiation Therapy Devices for Cancer and Brain DiseaseDignitaries from Sweden and Jordan attended the inauguration of two of Elekta's cancer care technologies, including an advanced linear accelerator used to deliver radiation to treat people with cancer and a Leksell Gamma Knife radiosurgery system, which is used to treat a range of neurosurgical and oncological brain indications. The ceremony was held on November 16 at King Hussein Cancer Center together with King Hussein Cancer Foundation in Amman. Representing Elekta, Caroline Leksell Cooke, Member of Elekta's Board of Directors and granddaughter of Professor Lars Leksell, inventor of the Gamma Knife, spoke of her pride in the company's collaboration with health care facilities in Jordan and support to improve the lives of some of the 11,500 people diagnosed with cancer each year. The first Elekta linac and Gamma Knife were installed in Jordan in 2005, with successive upgrades and new technology since. Today, a wide spectrum of cancer is managed with the country's 15 Elekta linacs, two Gamma Knife systems, and brachytherapy solutions. Their Majesties the King and Queen of Sweden, Her Royal Highness Princess Ghida Talal, who is Chairperson of KHCC, His Royal Highness Prince Talal bin Muhammad, Caroline Leksell Cooke, the Swedish Ambassador to Jordan H.E. Alexandra Rydmark, and Dr. Asem Mansour KHCC General Director, were among those attending the event. The inauguration ceremony was part of a three-day state visit by Sweden's King Carl XVI Gustaf and Queen Silvia, together with Sweden's Minister of Foreign Affairs, H.E.Tobias Billström. During their visit, they will also pay tribute to the 40th anniversary of Sweden's diplomatic presence in Jordan.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Director Kelly Londy was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 28Elekta AB (publ) Announces Elekta Esprit Receives FDA 510(k) ClearanceElekta AB (publ) announced that Elekta Esprit, a new Leksell Gamma Knife® radiosurgery platform, received FDA 510(k) clearance. This milestone makes the system available to clinicians and people with brain disease in the U.S., as well as opening the door to other countries where FDA approval is recognized. Leksell Gamma Knife has been designed as a gentler alternative to open surgery and conventional radiotherapy. It can target the smallest and most challenging intracranial tumors and lesions with minimal effect on healthy tissue. This vital precision safeguards motor, sensory and neurocognitive function to help protect the mind and the person. With a variety of innovations now available in a single platform, Esprit continues to offer clinicians the option of frameless or frame-based workflows with a frame that provides superior visualization. Remote accessibility and collaboration tools for the treatment team are designed to meet the needs of changing environments. Esprit provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery. Leksell Gamma Knife has over 50 years of clinical evidence and remains the gold standard of intracranial radiosurgery. The U.S. has the largest installed base of Gamma Knife systems, whose users have contributed to driving the standard of care forward. Continuous advances in its design have resulted in extremely fast automated treatment planning for clinicians, and Esprit is ideal for safely treating a broad range of indications, including multiple metastases, arteriovenous malformations, trigeminal neuralgia and vestibular schwannoma.
お知らせ • Oct 26Elekta Unity Demonstrates Promising Quality of Life Outcomes for Pancreas and Prostate Cancers At Astro Annual MeetingElekta announced two new reports from the MOMENTUM Study highlighting the clinical impact of Elekta Unity MR-Linac in treating pancreas and prostate cancers. The abstracts were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, in San Antonio, Texas. These reports add to a growing body of evidence showing that enhanced precision radiotherapy using MR-guided on-line adaptation may improve outcomes in both pancreas and prostate cancers, two common treatment indications for radiotherapy. Elekta Unity is the world’s first and only MR-Linac to unite diagnostic quality high field (1.5T) MRI with a linear accelerator to deliver unprecedented visibility and precision, thus enabling personalized radiotherapy. The MOMENTUM Study is the largest prospective international registry of high field MR-guided therapy, currently enrolling patients from 15 major cancer centers in North America, Europe and Australia. In the study of pancreas tumors, which are historically treatment resistant, 80 patients treated with an ablative radiation dose using MR-guided online adaption were enrolled and surveyed using standardized quality-of-life questionnaires. Patients reported limited adverse effects and stable global health status out to three months. Importantly, 67% of patients were alive one year after the end of treatment. In the study of prostate cancers, 218 patients were enrolled and followed with standardized quality-of-life questionnaires. Approximately half of the patients were treated using both MR-guidance and on-line adaptation functionality on Elekta Unity while the remaining half were treated using only MR-guidance without on-line adaptation. As expected, investigators observed a decline in quality-of-life scores three months after the end of treatment in the cohort treated with MR-guidance alone. However, no significant decline in quality of life was observed in the cohort of prostate cancers treated using both MR-guidance and on-line adaptation.
お知らせ • Sep 19Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD)Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD)
お知らせ • Aug 26+ 1 more updateElekta AB (publ) Elects Kelly Londy as a DirectorElekta AB (publ) announced that Kelly Londy was elected as a new Director at its Annual General Meeting held on 25 August 2022.
Reported Earnings • Aug 26First quarter 2023 earnings released: EPS: kr0.16 (vs kr0.33 in 1Q 2022)First quarter 2023 results: EPS: kr0.16 (down from kr0.33 in 1Q 2022). Revenue: kr3.33b (up 11% from 1Q 2022). Net income: kr60.0m (down 53% from 1Q 2022). Profit margin: 1.8% (down from 4.2% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.5%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany.
Upcoming Dividend • Aug 19Upcoming dividend of kr1.20 per shareEligible shareholders must have bought the stock before 26 August 2022. Payment date: 01 September 2022. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.2%).
Reported Earnings • Jul 13Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021)Full year 2022 results: EPS: kr3.02 (down from kr3.28 in FY 2021). Revenue: kr14.5b (up 5.7% from FY 2021). Net income: kr1.15b (down 8.0% from FY 2021). Profit margin: 7.9% (down from 9.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 9.4%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
お知らせ • Jul 09+ 1 more updateElekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023Elekta AB (publ) announced that they will report fiscal year 2023 results on May 25, 2023
Reported Earnings • May 26Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021)Full year 2022 results: EPS: kr3.02 (down from kr3.28 in FY 2021). Revenue: kr14.5b (up 5.7% from FY 2021). Net income: kr1.15b (down 8.0% from FY 2021). Profit margin: 7.9% (down from 9.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.4%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • May 26Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021/22The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.20) per share (paid in two installments) for the fiscal year 2021/22.
お知らせ • May 08Elekta Launches New Radiosurgery System: Elekta EspritElekta AB (publ) has evolved radiosurgery to an unprecedented level with the launch of Elekta Esprit. This latest and most advanced system will offer significantly faster automated treatment planning for clinicians, more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person. With a variety of innovations now available in a single platform, Esprit offers clinicians superior visualization, as well as remote accessibility and collaboration tools for the treatment team. And it provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Director Cecilia Wikström was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 26+ 2 more updatesElekta AB (publ) to Report Fiscal Year 2022 Final Results on Jul 08, 2022Elekta AB (publ) announced that they will report fiscal year 2022 final results on Jul 08, 2022
Recent Insider Transactions • Mar 10President of Brachy Solutions recently bought €30k worth of stockOn the 2nd of March, John Lapré bought around 4k shares on-market at roughly €7.41 per share. In the last 3 months, there was an even bigger purchase from another insider worth €145k. Insiders have collectively bought €2.1m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Mar 04Insider recently bought €49k worth of stockOn the 24th of February, Verena Schiller bought around 6k shares on-market at roughly €7.58 per share. In the last 3 months, there was an even bigger purchase from another insider worth €145k. Insiders have collectively bought €2.1m more in shares than they have sold in the last 12 months.
Reported Earnings • Feb 25Third quarter 2022 earnings: Revenues in line with analyst expectationsThird quarter 2022 results: Revenue: kr3.60b (flat on 3Q 2021). Net income: kr229.0m (down 29% from 3Q 2021). Profit margin: 6.4% (down from 9.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Feb 24Elekta AB (publ), Annual General Meeting, Aug 25, 2022Elekta AB (publ), Annual General Meeting, Aug 25, 2022.
Valuation Update With 7 Day Price Move • Feb 19Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €7.79, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 29x in the Medical Equipment industry in Germany. Total loss to shareholders of 32% over the past three years.
Upcoming Dividend • Feb 18Upcoming dividend of kr1.10 per shareEligible shareholders must have bought the stock before 25 February 2022. Payment date: 03 March 2022. Payout ratio is a comfortable 72% and the cash payout ratio is 80%. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (3.3%). Higher than average of industry peers (1.1%).
